Probing DNA damage in Rett syndrome neurons uncovers a role for MECP2 regulation of PARP1

A Morales1, E Korsakova2, N Mansooralavi3

  • 1Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA; Department of Molecular Cell and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.

Stem Cell Reports
|September 26, 2025
PubMed

Insights

Rett syndrome, caused by MECP2 loss, triggers neuronal dysfunction via DNA damage. Restoring PARP1 activity in these neurons reverses damage and developmental defects, suggesting PARP1 as a therapeutic target.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Rett syndrome is a neurodevelopmental disorder characterized by loss of motor skills and cognitive function.
  • Neurons in Rett syndrome models exhibit senescence and P53 activity, but the underlying cause of dysfunction is unclear.

Purpose of the Study:

  • To investigate the molecular mechanisms driving neuronal dysfunction in Methyl-CpG-binding protein 2 (MECP2)-null neurons.
  • To explore the role of DNA damage and repair pathways in Rett syndrome pathogenesis.

Main Methods:

  • Utilized human induced pluripotent stem cell (hiPSC)-derived isogenic lines to model MECP2 deficiency.
  • Investigated the interaction between MECP2 and DNA repair proteins, specifically PARP1.
  • Assessed the impact of restoring PARP1 activity on neuronal function.

Main Results:

  • MECP2-null neurons exhibit elevated DNA damage, which triggers molecular and physiological dysfunction.
  • MECP2 directly interacts with and regulates the activity of PARP1, a key DNA repair enzyme.
  • Restoring PARP1 activity in MECP2-deficient neurons ameliorated DNA damage, senescence, dendritic defects, and metabolic issues.

Conclusions:

  • Neuronal dysfunction in Rett syndrome is driven by elevated DNA damage, not solely senescence or P53 activity.
  • MECP2 plays a crucial role in regulating DNA repair via PARP1.
  • Modulating PARP1 activity presents a potential therapeutic strategy for Rett syndrome.